| Literature DB >> 30514831 |
Robert G Mannino1,2,3, David R Myers1,2,3, Erika A Tyburski1,2,3, Christina Caruso2, Jeanne Boudreaux2, Traci Leong4, G D Clifford1,5, Wilbur A Lam6,7,8.
Abstract
We introduce a paradigm of completely non-invasive, on-demand diagnostics that may replace common blood-based laboratory tests using only a smartphone app and photos. We initially targeted anemia, a blood condition characterized by low blood hemoglobin levels that afflicts >2 billion people. Our app estimates hemoglobin levels by analyzing color and metadata of fingernail bed smartphone photos and detects anemia (hemoglobin levels <12.5 g dL-1) with an accuracy of ±2.4 g dL-1 and a sensitivity of 97% (95% CI, 89-100%) when compared with CBC hemoglobin levels (n = 100 subjects), indicating its viability to serve as a non-invasive anemia screening tool. Moreover, with personalized calibration, this system achieves an accuracy of ±0.92 g dL-1 of CBC hemoglobin levels (n = 16), empowering chronic anemia patients to serially monitor their hemoglobin levels instantaneously and remotely. Our on-demand system enables anyone with a smartphone to download an app and immediately detect anemia anywhere and anytime.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30514831 PMCID: PMC6279826 DOI: 10.1038/s41467-018-07262-2
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Fig. 1Implementation of a smartphone app for measuring hemoglobin (Hgb). a A patient simply downloads the app onto their smartphone, opens the app, obtains a smartphone photo of his/her fingernail beds, and without the need for any blood sampling or additional smartphone attachments or external calibration tools, quantitatively measures blood Hgb levels. The patient first takes an image of their fingernails, and is then prompted by the app to tap on the screen to select the regions of interest corresponding to the nailbeds, and a result is then displayed on the smartphone screen. Images are screenshots and photos of actual operation of this app. b As smartphone images with fingernail irregularities such as camera flash reflections or leukonychia may affect Hgb level measurements, a quality control algorithm integrated within the Hgb level measurement app detects and omits those irregularities to preserve measurement integrity and accuracy. To that end, the user selects regions of interest from within the fingernail image, and any color values that fall outside of expected color ranges are excluded from Hgb measurement. In this example, when the quality control system was implemented to exclude the fingernail bed irregularities, Hgb level was measured to be 14.7 g dL−1, comparable to the patient’s CBC Hgb level of 15.3 g dL−1. Without the quality control algorithm, Hgb level was measured at 12.8 g dL−1, indicating that the algorithm resulted in a 76% reduction in error. Note that as the smartphone image-based algorithm is device-agnostic, the analysis of the smartphone images, and therefore the Hgb level measurements, could also be transmitted to another device (e.g., laptop, cloud-based server) for remote rather than on-board analysis
Comparison of currently existing anemia diagnostic technologies with the app
| Device | Non-invasive | Smartphone-based | Does not require additional equipment (aside from smartphone) | Low cost (<$25) | Accurate (LOA < 3 g dL−1) |
|---|---|---|---|---|---|
| Complete blood count hemoglobin levels (Gold Standard) | X | X | X | X | ✓ |
| Hemocue | X | X | X | X | ✓ |
| Masimo co-oximetry | ✓ | X | X | X | X |
| Conjunctival analysis | ✓ | ✓ | X | ✓ | X |
| WHO color scale | X | X | X | ✓ | X |
| HemaApp | ✓ | ✓ | X | ✓ | X |
| Smartphone Anemia App | ✓ | ✓ | ✓ | ✓ | ✓ |
Fig. 2The smartphone-based image analysis algorithm accurately measures Hgb levels. a The smartphone image analysis algorithm measures blood Hgb levels to within ±0.97 g dL−1 of the CBC Hgb level (r = 0.82, mean |error|). The solid line represents the ideal result where smartphone Hgb level is equal to the CBC Hgb level whereas the dashed line represents the actual data fit. Inset images illustrate example patient-sourced photos that were used to calculate Hgb level measurements. b The receiver-operating characteristic (ROC) analysis graphically illustrates the algorithm’s diagnostic performance against a random chance diagnosis (red line), with an area under the curve of 0.5, and a perfect diagnostic (green lines), with an area under the curve of 1. In the case of this noninvasive smartphone app Hgb measurement system (black line), the area under the curve of 0.88 suggests viable diagnostic performance of this algorithm. When using the WHO Hgb level cutoff of < 12.5 g dL−1, the sensitivity of the test is 97% (95% CI, 89–100%), n = 100 patients. c Bland–Altman analysis reveals minimal experimental bias with 0.2 g dL−1 average error, indicating that Hgb measurement is has a very small bias. The dashed line represents the relationship between the residual and the average of Hgb level measurements obtained from the CBC and the algorithm (r = 0.26). The solid red lines represent 95% limits of agreement (±2.4 g dL−1). n = 100
Fig. 3Diagnosis profile of our hemoglobin measurement patient population. Subjects with hemolytic anemia, healthy controls, cancer, other anemia (e.g., aplastic anemia), as well as various other blood disorders (e.g., such as thrombocytopenia, deep vein thrombosis, and hemophilia) participated in the study. These data represent the diagnosis profiles of the subjects shown in Fig. 2. n = 100
Diagnosis profile of subjects in clinical assessment
| Disorder | Number of patients |
|---|---|
|
| 211 |
| | 162 |
| Hgb SS | 126 |
| Hgb SC | 21 |
| Hgb Sβ+ | 8 |
| Hgb Sβ0 | 5 |
| | 17 |
| Major | 12 |
| Minor | 5 |
| Thrombocytopenia | 6 |
| Aplastic anemia | 2 |
| Deep vein thrombosis | 2 |
| Hemophilia | 2 |
| Microcytic anemia | 2 |
| Neutropenia | 3 |
| Pulmonary embolism | 2 |
| Anemia (unspecified) | 1 |
| Diamond blackfan anemia | 1 |
| Hemolytic anemia due to immunosuppression | 1 |
| Hyperbilirubinemia | 1 |
| Hypogammaglobulinemia | 1 |
| Iron-deficient anemia | 1 |
| Macrocytic anemia | 1 |
| Normocytic anemia | 1 |
| Pancytopenia | 1 |
| Paroxysmal nocturnal hemoglobinuria (PNH) | 1 |
| Purpura fulminans | 1 |
| Spherocytosis | 1 |
| Von Willebrand disease | 1 |
|
| 54 |
| Acute lymphoblastic leukemia | 29 |
| Hodgkin’s lymphoma | 6 |
| Acute myeloid leukemia | 5 |
| Diffuse large B cell lymphoma | 4 |
| Neuroblastoma | 3 |
| Osteosarcoma | 2 |
| Anaplastic ALK-positive large cell lymphoma | 1 |
| Burkitt’s lymphoma | 1 |
| Chronic myeloid leukemia | 1 |
| Ewing’s sarcoma | 2 |
| Extragonadal germ cell tumor of mediastinum | 1 |
| Germ cell neoplasm of the left testicle | 1 |
| Hepatoblastoma | 1 |
| Lymphoma (unspecified) | 1 |
| Rhabdomyosarcoma | 1 |
| Sacrococcygeal germ cell tumor | 1 |
| Spindle cell sarcoma | 1 |
| Synovial cell sarcoma | 1 |
| T lymphoblastic lymphoma | 1 |
| Wilm’s tumor | 1 |
| Healthy Control | 72 |
This study enrolled 337 individuals with a wide variety of diagnoses. Study subjects enrolled consisted of 162 patients with Sickle Cell disease (e.g., type SS, SC, Beta+, Beta 0), 34 patients various other anemias (e.g., Beta Thalassemia major and minor, Microcytic, macrocytic, normocytic, aplastic, iron deficient, and general anemia), 54 instances of several malignancies (e.g., Leukemia, Lymphoma, Sarcoma, Neuroblastoma, Germ Cell Tumor), as well as 15 patients suffering from various other blood conditions (e.g., Deep Vein Thrombosis, hyperbilirubinemia, Hypogammaglobulinemia, idiopathic thrombocytopenic purpura, Purpura fulminans, Pulmonary embolism, Neutropenia, Spherocytosis, Thrombocytopenia, Von Willebrand disease). Additionally, 72 healthy control subjects were enrolled in the study to ensure that a wide range of hemoglobin levels were represented
Fig. 4Personalized calibration further improves the accuracy of Hgb levels measurement. a Healthy and chronically transfused anemic patients were monitored over four weeks (i.e., over the course of a therapeutic blood transfusion cycle). CBC Hgb levels (white text) were used in conjunction with the images to generate a personalized algorithm for each individual. b The patient-specific algorithms were used to measure Hgb levels over a subsequent blood transfusion cycle. This patient-specific calibration improved the average error of Hgb level measurements to within 0.41 g dL−1 of the CBC Hgb level. Bland–Altman analysis shows negligible experimental bias in the data. A random effects model is used to statistically confirm consistency of average Hgb level measurement error between individual subjects. The average error (solid black line) indicates the Hgb measurement of the smartphone app is negligibly biased. The dashed line represents the correlation (r = −0.24) between the residual error and the average of Hgb level measurements obtained from the CBC and the algorithm. The solid red lines represent 95% limits of agreement (0.92 g dL−1). n = 4 patients, 4 measurements per patient
Fig. 5Background lighting and subject skin tone has minimal effect on app accuracy. Plotting measurement error against. a skin tone and b background lighting reveals low and negligible correlation (r = 0.13 and r = 0.00, respectively) in either case. Dashed lines indicate linear fit between the measurement error and the tested parameter (skin tone and background lighting, respectively). Inset images highlight a representative range of measured background skin tones and lighting conditions. n = 100 patients
Fig. 6App outperforms hematologists in physical exam-based hemaglobin measurement. Hematologists were able to estimate Hgb levels to within ±4.6 g dL−1 (a) (95% limits of agreement) with an ROC of 0.63 (c). The app outperforms the hematologists in both respects with Hgb level accuracy measurement to within ±1.0 g dL−1 (b) (95% limits of agreement) and an ROC of 0.94 (d). n = 50 subjects. Plots (a, c) represent the pooled results of 5 board-certified hematologists estimating blood hemoglobin levels based on images of patients fingernails